Clinical analysis of recombinant activated factor VIIa for 18 patients with severe bleeding.
- Author:
Zi-ling LIU
1
;
Lei YANG
;
Meng-meng LIU
;
Ou BAI
;
Jiu-wei CUI
;
Pei-tong LI
;
Wei LI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Blood Coagulation Disorders; drug therapy; Factor VIIa; therapeutic use; Female; Hemorrhage; drug therapy; Humans; Male; Middle Aged; Recombinant Proteins; therapeutic use; Retrospective Studies; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2012;33(5):409-411
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo find a kind of quick and effective haemostasis to decrease the mortality of severe bleeding.
METHODS18 severe bleeding patients with different cause received recombinant activated factor VIIa (rFVIIa) were analyzed retrospectively.
RESULTSOf total 18 cases with severe bleeding, 13 cases cured, 3 cases were effective, 2 cases ineffective. The total clinical effective rate is 88.89%. After using rFVIIa, the PT, APTT and fibrinogen level of 6 DIC patients returned to normal within 12 hours; 13 patients whose the amount of bleeding can be evaluated stopped bleeding quickly. The fastest onset time was 10 min.
CONCLUSIONrFVIIa can stanch severe bleeding for a variety of reasons rapidly and effectively, including coagulopathy, thrombocytopenia, and obstetric hemorrhage. Application of rFVIIa may decrease mortality, when conventional treatment is not valid.
